GHDX has been the topic of several other reports. ValuEngine upgraded Zimmer Biomet from a hold rating to a buy rating in a research note on Saturday. Zacks Investment Research lowered Hallmark Financial Services from a buy rating to a hold rating in a research note on Thursday, July 25th. Piper Jaffray Companies restated a buy rating on shares of Beigene in a research note on Thursday, June 20th. Needham & Company LLC set a $69.00 price target on Genomic Health and gave the company a buy rating in a research note on Wednesday, June 19th. Finally, Deutsche Bank set a $18.00 price target on Commercial Metals and gave the company a buy rating in a research note on Thursday, May 30th. Eleven investment analysts have rated the stock with a hold rating and three have given a buy rating to the stock. The company currently has an average rating of Hold and an average target price of $64.56.
NASDAQ GHDX opened at $74.00 on Friday. Genomic Health has a twelve month low of $50.77 and a twelve month high of $92.18. The company has a quick ratio of 5.67, a current ratio of 5.67 and a debt-to-equity ratio of 0.19. The firm has a market cap of $2.74 billion, a PE ratio of 70.48 and a beta of 1.07. The business’s 50-day simple moving average is $57.59.
In other news, insider James J. Vaughn sold 4,500 shares of the company’s stock in a transaction that occurred on Monday, July 8th. The stock was sold at an average price of $57.09, for a total value of $256,905.00. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link. Also, insider Steven Shak sold 50,000 shares of the company’s stock in a transaction that occurred on Wednesday, June 12th. The shares were sold at an average price of $51.38, for a total value of $2,569,000.00. The disclosure for this sale can be found here. Over the last quarter, insiders sold 152,025 shares of company stock worth $8,175,806. Corporate insiders own 31.30% of the company’s stock.
Several hedge funds have recently added to or reduced their stakes in GHDX. Northwestern Mutual Wealth Management Co. grew its stake in shares of Genomic Health by 166.0% in the 1st quarter. Northwestern Mutual Wealth Management Co. now owns 790 shares of the medical research company’s stock valued at $55,000 after purchasing an additional 493 shares during the period. Manchester Capital Management LLC acquired a new position in shares of Genomic Health in the 1st quarter worth approximately $56,000. Pearl River Capital LLC acquired a new position in shares of Genomic Health in the 1st quarter worth approximately $70,000. Zurcher Kantonalbank Zurich Cantonalbank boosted its holdings in shares of Genomic Health by 29.8% in the 2nd quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 1,923 shares of the medical research company’s stock worth $112,000 after acquiring an additional 441 shares in the last quarter. Finally, Advisor Group Inc. boosted its holdings in shares of Genomic Health by 34.9% in the 4th quarter. Advisor Group Inc. now owns 1,995 shares of the medical research company’s stock worth $129,000 after acquiring an additional 516 shares in the last quarter. Institutional investors own 95.06% of the company’s stock.
Genomic Health Company Profile
Genomic Health, Inc, a healthcare company, provides clinically actionable genomic information to personalize cancer treatment decisions in the United States and internationally. The company develops and commercializes genomic-based clinical laboratory services that analyze the underlying biology of cancer, which allows physicians and patients to make individualized treatment decisions.
Featured Article: Technical Analysis of Stocks, How Can It Help
Receive News & Ratings for Genomic Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Genomic Health and related companies with MarketBeat.com's FREE daily email newsletter.